Spruce Biosciences
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Spruce Biosciences sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Spruce Biosciences: 6 sponsored US clinical trials, none currently recruiting.
Spruce Biosciences sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is CAH - 21-Hydroxylase Deficiency, with 1 trials.
Upper-quartile sponsor footprint
Spruce Biosciences sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
6 total, page 1 of 1
A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens
NCT05370521
A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH
NCT05128942
A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH
NCT04544410
A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH
NCT04457336
Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia
NCT03687242
Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia
NCT03257462
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 6 |
Therapeutic Areas
How the Spruce Biosciences early-phase archive is shaped
6 indexed studies, none listed as recruiting (0% open); 2 completed (33%).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: CAH - 21-Hydroxylase Deficiency (1 trial), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Spruce Biosciences: archived-pipeline peers nationwide
Peers matched on 6 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Spruce Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 archived trials
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
Related
What to do with this Spruce Biosciences page
6 registered trials is a research-attention snapshot, not an endorsement of Spruce Biosciences or any single study.
- None of Spruce Biosciences's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- CAH - 21-Hydroxylase Deficiency is the condition Spruce Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See CAH - 21-Hydroxylase Deficiency trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Spruce Biosciences pipeline card: 6 registered trials from official public datasets.Report a data error.